Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 20 family member A21, pseudogene (ANKRD20A21P)
- Target
- ANKRD20A21P
- Molecular classification
- Other (pseudogene)
01
Overview
Ankyrin repeat domain 20 family member A21, pseudogene (ANKRD20A21P), is classified as a pseudogene, meaning it is a DNA sequence resembling a functional gene but has lost its protein-coding potential through mutation or inaccurate duplication. Pseudogenes, while traditionally labeled "junk DNA," are now known to potentially regulate protein-coding genes through several mechanisms, including acting as decoys for microRNAs or generating noncoding RNAs that modulate gene expression. There is no evidence that ANKRD20A21P itself is translated into a functional protein, nor is there indication that it serves as a therapeutic target or is involved in drug interactions or biomarker strategies. General disease relevance for pseudogenes is emerging, particularly in cancer, where some pseudogenes regulate the activity of tumor suppressors or oncogenes. However, no such role has been directly reported for ANKRD20A21P.
- Other names
- ANKRD20A21PAnkyrin repeat domain 20 family member A21 pseudogene
02
Mechanism of action
None
03
Biological functions
Possible regulation of gene expression through noncoding RNA mechanisms (inferred from general pseudogene biology, not specific to ANKRD20A21P)
04
Disease associations
No direct associations found; general pseudogenes may be involved in cancer or other diseases, not confirmed for this specific pseudogene
Beyond the preview
Go deeper on Ankyrin repeat domain 20 family member A21, pseudogene (ANKRD20A21P).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ankyrin repeat domain 20 family member A21, pseudogene (ANKRD20A21P).